Q-omics provides the consensus-scored FBXO5 profile across patient tissues and cancer cell-line models. FBXO5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FBXO5 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, FBXO5 RNA expression shows 22,810 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where FBXO5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO5 survival associations across molecular data types. FBXO5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO5 RNA expression–survival associations across cancer types. High FBXO5 expression shows unfavorable associations in KIRP, ACC, MESO, LIHC and KICH, but favorable associations in SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FBXO5 RNA expression.
This table summarizes FBXO5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO5 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, STAD, COAD and LUSC. The HNSC box plot shows higher FBXO5 RNA expression in tumor versus normal tissue (log2 FC = +1.527, t-test p < 0.001).
This table shows molecular features associated with FBXO5 in patient tissues and cancer cell lines. In patient samples, FBXO5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
